Drug Profile
Research programme: anaemia therapeutics - MDRNA
Latest Information Update: 05 Aug 2008
Price :
$50
*
At a glance
- Originator Nastech Pharmaceutical Company
- Developer MDRNA
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Anaemia
Most Recent Events
- 02 Jun 2006 Preclinical trials in Anaemia in USA (Intranasal)